-$0.11 EPS Expected for Sio Gene Therapies, Inc. (NASDAQ:SIOX) This Quarter

Equities analysts expect Sio Gene Therapies, Inc. (NASDAQ:SIOX) to report earnings of ($0.11) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Sio Gene Therapies’ earnings, with the highest EPS estimate coming in at ($0.02) and the lowest estimate coming in at ($0.20). Sio Gene Therapies reported earnings of ($0.54) per share during the same quarter last year, which would indicate a positive year over year growth rate of 79.6%. The business is scheduled to issue its next quarterly earnings results on Wednesday, June 9th.

According to Zacks, analysts expect that Sio Gene Therapies will report full-year earnings of ($0.73) per share for the current financial year, with EPS estimates ranging from ($0.88) to ($0.61). For the next year, analysts anticipate that the company will report earnings of ($0.81) per share, with EPS estimates ranging from ($0.84) to ($0.77). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Sio Gene Therapies.

Sio Gene Therapies (NASDAQ:SIOX) last released its quarterly earnings results on Monday, February 8th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09.

A number of brokerages have issued reports on SIOX. HC Wainwright initiated coverage on shares of Sio Gene Therapies in a research note on Friday. They set a “buy” rating and a $8.00 price target on the stock. Zacks Investment Research downgraded shares of Sio Gene Therapies from a “buy” rating to a “hold” rating in a research note on Saturday, April 3rd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Sio Gene Therapies presently has an average rating of “Buy” and an average price target of $10.92.

In other news, CEO Pavan Cheruvu acquired 100,000 shares of Sio Gene Therapies stock in a transaction dated Tuesday, March 23rd. The shares were acquired at an average cost of $2.48 per share, for a total transaction of $248,000.00. Following the acquisition, the chief executive officer now owns 180,426 shares of the company’s stock, valued at $447,456.48. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.20% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Planning purchased a new stake in Sio Gene Therapies during the fourth quarter worth approximately $129,000. GSA Capital Partners LLP purchased a new stake in shares of Sio Gene Therapies during the 4th quarter worth approximately $985,000. Primecap Management Co. CA acquired a new position in shares of Sio Gene Therapies in the 4th quarter valued at $146,000. Wells Fargo & Company MN purchased a new position in shares of Sio Gene Therapies in the 4th quarter valued at $100,000. Finally, Opaleye Management Inc. acquired a new stake in Sio Gene Therapies during the 4th quarter worth $5,560,000. Institutional investors and hedge funds own 24.12% of the company’s stock.

Shares of SIOX stock traded down $0.07 on Tuesday, hitting $2.63. The stock had a trading volume of 532,857 shares, compared to its average volume of 1,309,340. The company’s 50 day moving average price is $2.61 and its 200-day moving average price is $2.73. Sio Gene Therapies has a 1 year low of $1.86 and a 1 year high of $5.74. The firm has a market capitalization of $124.27 million and a P/E ratio of -1.33.

Sio Gene Therapies Company Profile

Sio Gene Therapies, Inc, a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis.

Read More: What are trading strategies for the 52-week high/low?

Get a free copy of the Zacks research report on Sio Gene Therapies (SIOX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sio Gene Therapies (NASDAQ:SIOX)

Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.